Yasmine Gabr, MD
Family Medicine · Columbia, SCNPI 1770935744
Payments from drug & device makers
Across 225 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$590
- Novo Nordisk$386
- AstraZeneca$374
- AbbVie$335
- Pfizer$229
- Exact Sciences$210
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,771100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 44 | $590 |
| Novo Nordisk | 22 | $386 |
| AstraZeneca(2 entities) | 25 | $374 |
| AbbVie | 22 | $335 |
| Pfizer | 12 | $229 |
| Exact Sciences | 12 | $210 |
| Boehringer Ingelheim | 12 | $201 |
| Amgen(2 entities) | 8 | $163 |
| Bayer | 6 | $119 |
| Astellas Pharma US Inc | 5 | $96 |
| GSK | 5 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $87 |
| Insulet Corporation | 3 | $78 |
| Phathom Pharmaceuticals, Inc. | 5 | $75 |
| Amarin Pharma, Inc. | 4 | $73 |
| Abbott | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Edwards Lifesciences | 3 | $53 |
| Lundbeck LLC | 2 | $50 |
| Shield Therapeutics Inc | 3 | $48 |
| Currax Pharmaceuticals LLC | 3 | $47 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Daiichi Sankyo Inc. | 2 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Inari Medical, Inc. | 1 | $28 |
| Stryker | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Medtronic | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Merck | 1 | $13 |
How this compares
$3,771 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $83,661 |
| JardianceEmpagliflozin | 41 | $51,708 |
| OzempicSemaglutide | 34 | $41,949 |
| RybelsusSemaglutide | 23 | $41,069 |
| JanuviaSitagliptin Phosphate | 23 | $24,108 |
| EliquisApixaban | 28 | $22,026 |
| FarxigaDapagliflozin Propanediol | 23 | $20,867 |
| XareltoRivaroxaban | 21 | $16,885 |
| MovantikNaloxegol Oxalate | 11 | $4,338 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $3,892 |
| Rosuvastatin Calcium | 234 | $3,518 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $3,455 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $2,033 |
| Gabapentin | 102 | $1,977 |
| Losartan Potassium | 174 | $1,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $590 | $83,66179 claims |
| Novo NordiskOzempic, Rybelsus | $386 | $83,01857 claims |
| Boehringer IngelheimJardiance | $201 | $51,70841 claims |
| MerckJanuvia | $13 | $24,10823 claims |
| PfizerEliquis | $229 | $22,02628 claims |
| AstraZenecaFarxiga | $374 | $20,86723 claims |
| AbbVieSynthroid | $335 | $64520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Columbia
- Conigliaro JonesColumbia$552K
- Damon DanielsColumbia$300K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Terry NagelColumbia$112K
- Steven BarnettColumbia$33K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.